Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study.
A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated meta-analyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).
Bachhuber
M A
MA
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021, USA. marcus.bachhuber@gmail.com
Gross
R
R
D000995:Antitubercular Agents / Q000627:therapeutic use*; D015897:Comorbidity; D015658:HIV Infections / Q000453:epidemiology*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D014376:Tuberculosis / Q000453:epidemiology* / Q000517:prevention & control*
D000995:Antitubercular Agents; D007538:Isoniazid